Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 10/20 | 0.61 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ARF6 | P62330 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326766 | 0.88 | IL1B (0.48) | IL1BTNFNLRP3HPGDS | |
| SCHEMBL29326525 | 0.86 | IL1B (0.67) | IL1BTNFNLRP3CNR1CNR2 | |
| SCHEMBL26434594 | 0.86 | IL1B (0.67) | IL1BTNFNLRP3CNR1CNR2 | |
| SCHEMBL29326722 | 0.85 | IL1B (0.63) | IL1BTNFNLRP3 | |
| SCHEMBL29974860 | 0.85 | IL1B (0.63) | IL1BTNFNLRP3 | |
| SCHEMBL29326781 | 0.82 | IL1B (0.43) | IL1BNLRP3SLC6A3CNR1CNR2 | |
| SCHEMBL29326772 | 0.82 | IL1B (0.65) | IL1BTNFNLRP3PIM1PIM2 | |
| SCHEMBL29326622 | 0.77 | IL1B (0.48) | IL1BTNFNLRP3HPGDS | |
| SCHEMBL29326752 | 0.77 | KCNH2 (0.44) | IL1BNLRP3CNR1CNR2 | |
| SCHEMBL29326790 | 0.76 | HPGDS (0.38) | IL1BNLRP3HPGDSSLC6A3ARF6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885TNF 67/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.